BioMarin Pharmaceutical

About:

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Website: https://www.biomarin.com

Description:

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Total Funding Amount:

$586M

Estimated Revenue Range:

$1B to $10B

Headquarters Location:

San Rafael, California, United States

Founded Date:

1997-03-01

Contact Email:

info(AT)bmrn.nl

Founders:

Christopher Starr, Grant Denison, John Klock

Number of Employees:

1001-5000

Last Funding Date:

2020-05-11

IPO Status:

Public

© 2025 bioDAO.ai